论文部分内容阅读
目的:研究丹葶肺心颗粒治疗哮喘缓解期疗效及对患者痰液炎症因子的影响。方法:研究对象为2012年6月到2014年6月我院收诊的140哮喘患者,均处于缓解期。抛硬币法分为2组(各70例)。对照组给予常规治疗,观察组另外服用丹葶肺心颗粒,对比两组治疗前后相关指标变化。结果:(1)治疗8周后,观察组FEV1%预计值、FEV1/FVC和PEFR值分别为(71.94±3.42%、79.99±3.57%、5.38±0.42L/s),均明显高于对照组(67.48±3.37%、72.16±3.48%、4.96±0.38L/s)。(2)治疗8周后,观察组痰液炎症因子ECP、IL-8和TNF-ɑ水平分别为(114.9±20.2μg/L、147.1±16.5ng/L、149.6±20.8ng/L),均明显低于对照组(153.2±21.8μg/L、169.4±18.5ng/L、187.6±22.9ng/L)。(3)8周的治疗期之后6个月内,观察组SGRQ评分、急性发作次数和呼吸道感染次数分别为(41.56±3.01分、1.28±0.46次、1.50±0.40次),均明显低于对照组(49.92±3.05分、2.01±0.52次、2.31±0.46次)。(4)服药期间,对照组出现5.71%的不良反应,观察组2.86%。结论:丹葶肺心颗粒有助于改善处于哮喘缓解期的患者肺通气指标和炎症水平,降低发病次数。
Objective: To study the effect of Danxiongxiongxin Granule in the treatment of asthma and its effect on sputum inflammatory factors. Methods: The subjects were 140 asthma patients admitted to our hospital from June 2012 to June 2014, all in remission. Coin law is divided into 2 groups (70 cases each). The control group was given routine treatment. The observation group received Danxiong Pulmonary Heart Granule separately. The changes of related indexes before and after treatment were compared between the two groups. Results: (1) After 8 weeks of treatment, the predicted values of FEV1%, FEV1 / FVC and PEFR in the observation group were (71.94 ± 3.42%, 79.99 ± 3.57%, 5.38 ± 0.42L / s) (67.48 ± 3.37%, 72.16 ± 3.48%, 4.96 ± 0.38 L / s). (2) After 8 weeks of treatment, the levels of inflammatory cytokines ECP, IL-8 and TNF-in the observation group were (114.9 ± 20.2μg / L, 147.1 ± 16.5ng / L, 149.6 ± 20.8ng / L) Was significantly lower than the control group (153.2 ± 21.8μg / L, 169.4 ± 18.5ng / L, 187.6 ± 22.9ng / L). (3) Within 6 months after the 8-week treatment, the SGRQ scores, the number of acute attacks and the number of respiratory infections in the observation group were (41.56 ± 3.01 points, 1.28 ± 0.46 times and 1.50 ± 0.40 times), respectively, which were significantly lower than those in the control Group (49.92 ± 3.05 points, 2.01 ± 0.52 times, 2.31 ± 0.46 times). (4) during the medication, the control group showed adverse reactions 5.71%, observation group 2.86%. Conclusion: Danfanxiongxin granule can help to improve pulmonary aeration index and inflammation in patients with remission of asthma, and reduce the frequency of onset.